Pneumococcal disease Clinical Trials

8 recruitingLast updated: July 25, 2026

There are 8 actively recruiting pneumococcal disease clinical trials across 7 countries. Studies span Phase 3, Phase 4, Phase 1. Top locations include South Euclid, Ohio, United States, Simpsonville, South Carolina, United States, Birmingham, Alabama, United States. Updated daily from ClinicalTrials.gov.


Pneumococcal disease Trials at a Glance

8 actively recruiting trials for pneumococcal disease are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 3 with 5 trials, with the heaviest enrollment activity in South Euclid, Simpsonville, and Birmingham. Lead sponsors running pneumococcal disease studies include Pfizer, Aimei Vacin BioPharm (Zhejiang) Co., Ltd., and GPN Vaccines.

Browse pneumococcal disease trials by phase

About Pneumococcal disease Clinical Trials

Looking for clinical trials for Pneumococcal disease? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pneumococcal disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pneumococcal disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 4

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

VaccinePneumococcal disease
University of Alabama at Birmingham70 enrolled1 locationNCT07135453
Recruiting
Phase 3

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

Pneumococcal disease
Pfizer3,230 enrolled97 locationsNCT07629440
Recruiting
Phase 3

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

Pneumococcal disease
Pfizer2,400 enrolled21 locationsNCT07573462
Recruiting
Phase 3

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

Pneumococcal disease
Pfizer1,200 enrolled44 locationsNCT07660198
Recruiting
Phase 1

Serum Collection Study for Assay Development

Pneumococcal Disease, InvasivePneumococcal disease
GPN Vaccines12 enrolled1 locationNCT07205289
Recruiting
Phase 4

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

Pneumococcal CarriagePneumococcal disease
University of Oxford106 enrolled2 locationsNCT06731374
Recruiting
Phase 3

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

Pneumococcal disease
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.1,920 enrolled1 locationNCT06044077
Recruiting
Phase 3Phase 4

A randomised controlled trial of pneumococcal conjugate vaccines Synflorix and Prevenar13 in sequence or alone in high-risk Indigenous infants (PREV-IX): immunogenicity, carriage and otitis media outcomes

Non-typeable Haemophilus influenzae diseaseOtitis media in Indigenous infantsPneumococcal disease
Menzies School of Health Research425 enrolled1 locationACTRN12610000544077